Ex vivo expansion of hematopoietic progenitor cells and mature cells

被引:66
作者
McNiece, I
Briddell, R
机构
[1] Univ Colorado, BMT Program B116, HSC, Denver, CO 80262 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
expansion; stem cells; progenitors; transplantation; cord blood;
D O I
10.1016/S0301-472X(00)00610-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hematopoietic cells have the potential for providing benefit in a variety of clinical settings. These include tells for support of patients undergoing high-dose chemotherapy, as a target for replacement gent! therapy, and as a source of cells for immunotherapy. The limitation to many of these applications has been the total absolute number of defined target cells. Therefore many investigators have explored methods to culture hematopoietic cells in vitro to increase the numbers of these cells, Studies attempting to expand hematopoietic stem cells, progenitor cells, and mature cells in vitro have become possible over the past decade due to the availability of recombinant growth factors and cell selection technologies. To date, no studies have demonstrated convincing data on the expansion of true stem cells, and so the focus of this review is the expansion of committed progenitor cells and mature cells. A number of clinical studies have been preformed using: a variety of culture conditions, and several studies are currently in progress that explore the use of ex vivo expanded cells. These studies will be discussed in this review. There are evolving data that suggest that there are real clinical benefits associated with the use of the expanded cells; however, we are still at the early stages of understanding how to optimally culture different cell populations. The next decade should determine what culture conditions and what cell populations are needed for a range of clinical applications. (C) 2001 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 38 条
  • [1] CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity
    Alcorn, MJ
    Holyoake, TL
    Richmond, L
    Pearson, C
    Farrell, E
    Kyle, B
    Dunlop, DJ
    Fitzsimons, E
    Steward, WP
    Pragnell, IB
    Franklin, IM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1839 - 1847
  • [2] Andrews R. G., 1997, Blood, V90, p92A
  • [3] [Anonymous], [No title captured]
  • [4] BERNSTEIN ID, 1991, BLOOD, V77, P2316
  • [5] BOTNICK LE, 1979, BLOOD CELLS, V5, P195
  • [6] BRADLEY TR, 1985, HEMATOPOIETIC STEM C, P39
  • [7] BREEMS DA, 1994, LEUKEMIA, V12, P356
  • [8] Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells
    Briddell, RA
    Kern, BP
    Zilm, KL
    Stoney, GB
    McNiece, IK
    [J]. JOURNAL OF HEMATOTHERAPY, 1997, 6 (02): : 145 - 150
  • [9] RETRACTED: RECONSTITUTION OF HEMATOPOIESIS AFTER HIGH-DOSE CHEMOTHERAPY BY AUTOLOGOUS PROGENITOR CELLS GENERATED EX-VIVO (RETRACTED ARTICLE. SEE VOL 345, PG 64, 2001)
    BRUGGER, W
    HEIMFELD, S
    BERENSON, RJ
    MERTELSANN, R
    KANZ, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (05) : 283 - 287
  • [10] Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation
    Cairo, MS
    Wagner, JE
    [J]. BLOOD, 1997, 90 (12) : 4665 - 4678